AAS
GSK icon

Avantax Advisory Services’s GSK GSK Stock Holding History

Avantax Advisory Services’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$5.36M Buy
139,607
+16,807
+14% +$642K 0.03% 431
2025
Q1 		$4.76M Buy
122,800
+19,147
+18% +$701K 0.03% 427
2024
Q4 		$3.51M Buy
103,653
+5,608
+6% +$202K 0.02% 501
2024
Q3 		$4.01M Sell
98,045
-21,748
-18% -$890K 0.03% 456
2024
Q2 		$4.61M Buy
119,793
+46,159
+63% +$1.94M 0.03% 398
2024
Q1 		$3.16M Sell
73,634
-1,420
-2% -$58.6K 0.03% 417
2023
Q4 		$2.78M Sell
75,054
-1,786
-2% -$64.1K 0.03% 414
2023
Q3 		$2.79M Buy
76,840
+14,689
+24% +$521K 0.03% 373
2023
Q2 		$2.22M Buy
62,151
+5,051
+9% +$181K 0.03% 426
2023
Q1 		$2.03M Buy
57,100
+6,100
+12% +$213K 0.02% 442
2022
Q4 		$1.79M Buy
51,000
+3,252
+7% +$108K 0.02% 454
2022
Q3 		$1.41M Buy
47,748
+1,469
+3% +$55.7K 0.02% 459
2022
Q2 		$2.52M Sell
46,279
-578
-1% -$31.9K 0.04% 334
2022
Q1 		$2.56M Buy
46,857
+3,830
+9% +$208K 0.04% 320
2021
Q4 		$2.37M Buy
43,027
+5,578
+15% +$290K 0.04% 336
2021
Q3 		$1.79M Buy
37,449
+6,362
+20% +$320K 0.03% 362
2021
Q2 		$1.55M Sell
31,087
-195
-0.6% -$9.37K 0.03% 383
2021
Q1 		$1.4M Buy
31,282
+1,545
+5% +$70.1K 0.03% 365
2020
Q4 		$1.37M Sell
29,737
-25,061
-46% -$1.15M 0.03% 335
2020
Q3 		$2.59M Buy
54,798
+29,868
+120% +$1.5M 0.04% 315
2020
Q2 		$1.27M Buy
24,930
+1,020
+4% +$52.3K 0.04% 301
2020
Q1 		$1.14M Buy
23,910
+935
+4% +$49.9K 0.03% 279
2019
Q4 		$1.35M Buy
22,975
+16,410
+250% +$913K 0.03% 282
2019
Q3 		$349K Sell
6,565
-1,032
-14% -$53.1K 0.01% 397
2019
Q2 		$380K Buy
7,597
+321
+4% +$16.1K 0.02% 347
2019
Q1 		$380K Buy
7,276
+42
+0.6% +$2.1K 0.02% 312
2018
Q4 		$350K Buy
+7,234
New +$356K 0.06% 274

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Avantax Advisory Services's GSK Position: Q2 2025 in Review

Avantax Advisory Services increased its GSK (GSK) stake by 14% in Q2 2025, buying an estimated $642K and bringing the position to 139,607 shares worth $5.36M. The position accounts for 0.03% of the portfolio, ranked #431.

Avantax Advisory Services first reported a position in GSK in Q4 2018 and has held it in 27 quarters since. 890 funds tracked by Wall St. Rank hold GSK as of Q2 2025.

  • Avantax Advisory Services held 139,607 shares of GSK worth $5.36M as of Q2 2025.
  • Avantax Advisory Services bought 16,807 GSK shares in Q2 2025, an estimated $642K.
  • GSK made up 0.03% of Avantax Advisory Services's portfolio in Q2 2025, its #431 holding.
  • Avantax Advisory Services first reported a position in GSK in Q4 2018 and has held it in 27 quarters since.
  • 890 funds tracked by Wall St. Rank held GSK as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.